T1	tradename 113 118	DOXIL
T2	tradename 180 193	DOXIL. DOXIL
T3	activeingredient 195 220	doxorubicin hydrochloride
T4	nanoparticle 221 229	liposome
T5	routeofadministration 246 257	intravenous
T6	fdaapprovaldate 285 289	1995
T7	activeingredient 519 534	doxorubicin HCl
T8	dose 546 556	550 mg/m2.
T9	tradename 1256 1256	
T10	chemoclass 1263 1303	anthracycline topoisomerase II inhibitor
T11	indication 1329 1343	Ovarian cancer
T12	indication 1406 1435	AIDS-related Kaposi's Sarcoma
T13	indication 1529 1545	Multiple Myeloma
T14	co-administereddrug 1572 1582	bortezomib
T15	co-administereddrug 1628 1638	bortezomib
T16	tradename 1765 1770	DOXIL
T17	indication 2026 2041	Ovarian cancer:
T18	dose 2042 2050	50 mg/m2
T19	routeofadministration 2051 2053	IV
T20	frequency 2054 2067	every 4 weeks
T21	indication 2084 2114	AIDS-related Kaposi's Sarcoma:
T22	dose 2115 2123	20 mg/m2
T23	routeofadministration 2124 2126	IV
T24	frequency 2127 2140	every 3 weeks
T25	indication 2157 2174	Multiple Myeloma:
T26	dose 2175 2183	30 mg/m2
T27	routeofadministration 2184 2186	IV
T28	co-administereddrug 2206 2216	bortezomib
T29	activeingredient 2300 2314	 hydrochloride
T30	nanoparticle 2321 2330	liposomal
T31	activeingredient 2506 2521	doxorubicin HCl
T32	tradename 2544 2549	DOXIL
T33	adversereaction 2637 2655	Hand-Foot Syndrome
T34	adversereaction 2737 2759	Embryo fetal Toxicity:
T35	adversereaction 2983 3129	asthenia, fatigue, fever, anorexia, nausea, vomiting, stomatitis, diarrhea, constipation, hand-foot syndrome, rash, neutropenia, thrombocytopenia,
T36	adversereaction 3134 3140	anemia
T37	company 3193 3213	Janssen Products, LP
T38	indication 3604 3618	Ovarian Cancer
T39	indication 3624 3653	AIDS-Related Kaposi's Sarcoma
T40	indication 3659 3675	Multiple Myeloma
T41	indication 3741 3755	Ovarian Cancer
T42	indication 3761 3790	AIDS-Related Kaposi's Sarcoma
T43	indication 3796 3812	Multiple Myeloma
T44	adversereaction 4026 4040	Cardiomyopathy
T45	adversereaction 4046 4072	Infusion-Related Reactions
T46	adversereaction 4078 4102	Hand-Foot Syndrome (HFS)
T47	adversereaction 4108 4132	Secondary Oral Neoplasms
T48	adversereaction 4138 4159	Embryo fetal Toxicity
T49	indication 4672 4686	Ovarian Cancer
T50	indication 4693 4722	AIDS-Related Kaposi's Sarcoma
T51	indication 4729 4745	Multiple Myeloma
T52	tradename 5158 5163	DOXIL
T53	activeingredient 5165 5180	doxorubicin HCl
T54	nanoparticle 5181 5189	liposome
T55	adversereaction 5211 5229	myocardial damage,
T56	adversereaction 5241 5266	congestive heart failure,
T57	activeingredient 5299 5314	doxorubicin HCl
T58	dose 5326 5336	550 mg/m2.
T59	tradename 5416 5422	DOXIL,
T60	adversereaction 5435 5449	cardiotoxicity
T61	dose 5509 5522	450-550 mg/m2
T62	adversereaction 5876 5986	flushing, shortness of breath, facial swelling, headache, chills, back pain, tightness in the chest or throat,
T63	adversereaction 5994 6005	hypotension
T64	tradename 6065 6071	DOXIL.
T65	indication 6249 6263	Ovarian Cancer
T66	tradename 6265 6270	DOXIL
T67	indication 6319 6333	ovarian cancer
T68	indication 6415 6444	AIDS-Related Kaposi's Sarcoma
T69	tradename 6445 6450	DOXIL
T70	indication 6485 6514	AIDS-related Kaposi's sarcoma
T71	indication 6609 6625	Multiple Myeloma
T72	tradename 6626 6632	DOXIL,
T73	co-administereddrug 6653 6664	bortezomib,
T74	indication 6713 6729	multiple myeloma
T75	co-administereddrug 6763 6773	bortezomib
T76	tradename 6898 6903	DOXIL
T77	activeingredient 6908 6923	doxorubicin HCl
T78	routeofadministration 6990 7001	intravenous
T79	indication 7122 7136	Ovarian Cancer
T80	tradename 7161 7166	DOXIL
T81	dose 7170 7178	50 mg/m2
T82	routeofadministration 7179 7192	intravenously
T83	frequency 7209 7222	every 28 days
T84	indication 7280 7309	AIDS-Related Kaposi's Sarcoma
T85	tradename 7334 7339	DOXIL
T86	dose 7343 7351	20 mg/m2
T87	routeofadministration 7352 7365	intravenously
T88	frequency 7382 7395	every 21 days
T89	indication 7453 7469	Multiple Myeloma
T90	tradename 7494 7499	DOXIL
T91	dose 7503 7511	30 mg/m2
T92	routeofadministration 7512 7525	intravenously
T93	frequency 7542 7571	on day 4 of each 21-day cycle
T94	duration 7576 7588	eight cycles
T95	tradename 7655 7660	DOXIL
T96	co-administereddrug 7667 7677	bortezomib
T97	tradename 7794 7799	DOXIL
T98	adversereaction 8161 8192	Hand-Foot Syndrome, Stomatitis,
T99	adversereaction 8252 8276	Hand-Foot Syndrome (HFS)
T100	tradename 8778 8783	DOXIL
T101	tradename 9203 9208	DOXIL
T102	tradename 9509 9514	DOXIL
T103	adversereaction 9548 9558	Stomatitis
T104	tradename 9919 9924	DOXIL
T105	tradename 10407 10413	DOXIL.
T106	tradename 10653 10659	DOXIL.
T107	adversereaction 10675 10691	Thrombocytopenia
T108	tradename 11308 11313	DOXIL
T109	co-administereddrug 11365 11375	Bortezomib
T110	tradename 11386 11391	DOXIL
T111	adversereaction 12014 12030	neuropathic pain
T112	adversereaction 12034 12056	peripheral neuropathy,
T113	tradename 12096 12102	DOXIL.
T114	co-administereddrug 12112 12122	bortezomib
T115	tradename 12218 12223	DOXIL
T116	inactiveingredient 12258 12266	Dextrose
T117	inactiveingredient 12352 12360	Dextrose
T118	tradename 12421 12426	DOXIL
T119	tradename 12782 12787	DOXIL
T120	tradename 13049 13054	DOXIL
T121	tradename 13124 13129	DOXIL
T122	tradename 13833 13838	DOXIL
T123	tradename 13929 13934	DOXIL
T124	tradename 14054 14060	DOXIL:
T125	activeingredient 14061 14076	doxorubicin HCl
T126	nanoparticle 14077 14086	liposomal
T127	dose 14123 14133	20mg/10 mL
T128	dose 14138 14147	50mg/25mL
T129	activeingredient 14148 14163	doxorubicin HCl
T130	nanoparticle 14186 14195	liposomal
T131	tradename 14229 14234	DOXIL
T132	activeingredient 14350 14365	doxorubicin HCl
T133	adversereaction 14436 14450	Cardiomyopathy
T134	activeingredient 14452 14467	Doxorubicin HCl
T135	adversereaction 14482 14500	myocardial damage,
T136	adversereaction 14511 14542	acute left ventricular failure.
T137	adversereaction 14555 14569	cardiomyopathy
T138	activeingredient 14575 14590	doxorubicin HCl
T139	tradename 14681 14686	DOXIL
T140	adversereaction 14708 14724	cardiac toxicity
T141	tradename 14830 14836	DOXIL,
T142	adversereaction 14849 14863	cardiotoxicity
T143	dose 14923 14936	450-550 mg/m2
T144	adversereaction 14939 14953	Cardiotoxicity
T145	adversereaction 15259 15283	congestive heart failure
T146	adversereaction 15315 15330	cardiotoxicity.
T147	tradename 15426 15432	DOXIL,
T148	tradename 15540 15545	DOXIL
T149	tradename 15990 15996	DOXIL:
T150	adversereaction 15997 16204	flushing, shortness of breath, facial swelling, headache, chills, chest pain, back pain, tightness in the chest and throat, fever, tachycardia, pruritus, rash, cyanosis, syncope, bronchospasm, asthma, apnea,
T151	adversereaction 16209 16221	hypotension.
T152	indication 16319 16333	ovarian cancer
T153	tradename 16347 16352	DOXIL
T154	tradename 16547 16552	DOXIL
T155	tradename 16855 16861	DOXIL.
T156	tradename 16871 16876	DOXIL
T157	tradename 17120 17125	DOXIL
T158	adversereaction 17200 17224	Hand-Foot Syndrome (HFS)
T159	tradename 17285 17290	DOXIL
T160	tradename 17381 17394	DOXIL-treated
T161	tradename 17517 17522	DOXIL
T162	tradename 17634 17639	DOXIL
T163	tradename 17739 17744	DOXIL
T164	adversereaction 17785 17833	Secondary Oral Neoplasms Secondary oral cancers,
T165	adversereaction 17844 17868	squamous cell carcinoma,
T166	tradename 17979 17985	DOXIL.
T167	tradename 18047 18052	DOXIL
T168	adversereaction 18220 18242	secondary oral cancer.
T169	nanoparticle 18313 18322	liposomal
T170	activeingredient 18323 18334	doxorubicin
T171	adversereaction 18364 18377	skin toxicity
T172	adversereaction 18382 18391	mucositis
T173	adversereaction 18459 18486	oral secondary malignancies
T174	adversereaction 18669 18689	Embryofetal Toxicity
T175	tradename 18712 18717	DOXIL
T176	tradename 18843 18848	DOXIL
T177	tradename 19078 19083	DOXIL
T178	adversereaction 19262 19276	Cardiomyopathy
T179	adversereaction 19324 19350	Infusion-Related Reactions
T180	adversereaction 19398 19416	Hand-Foot Syndrome
T181	adversereaction 19464 19488	Secondary Oral Neoplasms
T182	tradename 19584 19589	DOXIL
T183	adversereaction 19594 19708	asthenia, fatigue, fever, nausea, stomatitis, vomiting, diarrhea, constipation, anorexia, hand-foot syndrome, rash
T184	adversereaction 19713 19742	neutropenia, thrombocytopenia
T185	adversereaction 19747 19754	anemia.
T186	tradename 20064 20069	DOXIL
T187	indication 20116 20131	ovarian cancer,
T188	indication 20150 20180	AIDS-related Kaposi's sarcoma,
T189	indication 20203 20220	multiple myeloma.
T190	tradename 20306 20311	DOXIL
T191	indication 20315 20329	ovarian cancer
T192	indication 20334 20364	AIDS-Related Kaposi's sarcoma.
T193	indication 20380 20394	Ovarian Cancer
T194	indication 20478 20492	ovarian cancer
T195	tradename 20506 20511	DOXIL
T196	tradename 20651 20656	DOXIL
T197	tradename 21219 21224	DOXIL
T198	adversereaction 21271 21282	Neutropenia
T199	adversereaction 21331 21337	Anemia
T200	adversereaction 21387 21403	Thrombocytopenia
T201	tradename 21602 21607	DOXIL
T202	adversereaction 21752 21760	Asthenia
T203	adversereaction 21771 21776	Fever
T204	adversereaction 21789 21813	Mucous Membrane Disorder
T205	adversereaction 21827 21836	Back Pain
T206	adversereaction 21851 21860	Infection
T207	adversereaction 21874 21882	Headache
T208	adversereaction 21906 21912	Nausea
T209	adversereaction 21923 21933	Stomatitis
T210	adversereaction 21946 21954	Vomiting
T211	adversereaction 21966 21974	Diarrhea
T212	adversereaction 21989 21997	Anorexia
T213	adversereaction 22012 22021	Dyspepsia
T214	adversereaction 22044 22053	Dizziness
T215	adversereaction 22078 22089	Pharyngitis
T216	adversereaction 22102 22109	Dyspnea
T217	adversereaction 22124 22139	Cough increased
T218	adversereaction 22171 22189	Hand-foot syndrome
T219	adversereaction 22202 22206	Rash
T220	adversereaction 22221 22229	Alopecia
T221	indication 22319 22333	ovarian cancer
T222	frequency 22358 22374	every four weeks
T223	adversereaction 22578 22655	vasodilation, tachycardia, deep vein thrombosis, hypotension, cardiac arrest.
T224	adversereaction 22668 22750	oral moniliasis, mouth ulceration, esophagitis, dysphagia, rectal bleeding, ileus.
T225	adversereaction 22779 22790	ecchymosis.
T226	adversereaction 22819 22906	dehydration, weight loss, hyperbilirubinemia, hypokalemia, hypercalcemia, hyponatremia.
T227	adversereaction 22917 22951	somnolence, dizziness, depression.
T228	adversereaction 22966 23008	rhinitis, pneumonia, sinusitis, epistaxis.
T229	adversereaction 23031 23206	pruritus, skin discoloration, vesiculobullous rash, maculopapular rash, exfoliative dermatitis, herpes zoster, dry skin, herpes simplex, fungal dermatitis, furunculosis, acne.
T230	adversereaction 23224 23267	conjunctivitis, taste perversion, dry eyes.
T231	adversereaction 23278 23333	urinary tract infection, hematuria, vaginal moniliasis.
T232	indication 23349 23378	AIDS-Related Kaposi's Sarcoma
T233	indication 23462 23491	AIDS-related Kaposi's sarcoma
T234	tradename 23549 23554	DOXIL
T235	dose 23590 23604	10 to 40 mg/m2
T236	frequency 23605 23624	every 2 to 3 weeks.
T237	dose 23818 23826	20 mg/m2
T238	tradename 23830 23835	DOXIL
T239	frequency 23836 23854	every 2 to 3 weeks
T240	duration 23881 23891	4.2 months
T241	duration 23899 23920	1 day to 26.6 months)
T242	dose 23953 23962	120 mg/m2
T243	dose 23970 23989	3.3 to 798.6 mg/m2)
T244	dose 24036 24045	450 mg/m2
T245	indication 25216 25245	AIDS-related Kaposi's sarcoma
T246	adversereaction 25259 25456	myelosuppression, cardiac adverse reactions, infusion-related reactions, toxoplasmosis, HFS, pneumonia, cough/dyspnea, fatigue, optic neuritis, progression of a non-KS tumor, allergy to penicillin,
T247	tradename 25559 25564	DOXIL
T248	indication 25569 25598	AIDS-related Kaposi's sarcoma
T249	indication 25706 25735	AIDS-Related Kaposi's Sarcoma
T250	indication 25809 25847	AIDS-Related Kaposi's Kaposi's Sarcoma
T251	adversereaction 25875 25886	Neutropenia
T252	adversereaction 25931 25937	Anemia
T253	adversereaction 25980 25996	Thrombocytopenia
T254	indication 26541 26570	AIDS-Related Kaposi's Sarcoma
T255	indication 26649 26692	AIDS-Related AIDS-Related Kaposi's Sarcoma
T256	adversereaction 26729 26735	Nausea
T257	adversereaction 26744 26752	Asthenia
T258	adversereaction 26760 26765	Fever
T259	adversereaction 26772 26780	Alopecia
T260	adversereaction 26787 26816	Alkaline Phosphatase Increase
T261	adversereaction 26825 26833	Vomiting
T262	adversereaction 26840 26848	Diarrhea
T263	adversereaction 26855 26865	Stomatitis
T264	adversereaction 26872 26887	Oral Moniliasis
T265	indication 27534 27564	AIDS-related Kaposi's sarcoma.
T266	adversereaction 27602 27660	headache, back pain, infection, allergic reaction, chills.
T267	adversereaction 27679 27716	chest pain, hypotension, tachycardia.
T268	adversereaction 27730 27760	herpes simplex, rash, itching.
T269	adversereaction 27774 27812	mouth ulceration, anorexia, dysphagia.
T270	adversereaction 27842 27889	SGPT increase, weight loss, hyperbilirubinemia.
T271	adversereaction 27899 27941	dyspnea, pneumonia, dizziness, somnolence.
T272	adversereaction 27984 28019	sepsis, moniliasis, cryptococcosis.
T273	adversereaction 28038 28182	thrombophlebitis, cardiomyopathy, palpitation, bundle branch block, congestive heart failure, heart arrest, thrombosis, ventricular arrhythmia.
T274	adversereaction 28196 28206	hepatitis.
T275	adversereaction 28246 28257	dehydration
T276	adversereaction 28273 28301	cough increase, pharyngitis.
T277	adversereaction 28325 28359	maculopapular rash, herpes zoster.
T278	adversereaction 28378 28411	taste perversion, conjunctivitis.
T279	tradename 28506 28511	DOXIL
T280	dose 28513 28522	30 mg/m2)
T281	co-administereddrug 28555 28565	bortezomib
T282	dose 28567 28576	1.3 mg/m2
T283	routeofadministration 28577 28581	i.v.
T284	frequency 28613 28627	every 3 weeks,
T285	tradename 28717 28722	DOXIL
T286	co-administereddrug 28725 28735	bortezomib
T287	duration 28790 28800	4.5 months
T288	duration 28808 28831	21 days to 13.5 months)
T289	tradename 29031 29036	DOXIL
T290	co-administereddrug 29057 29067	bortezomib
T291	indication 29072 29089	multiple myeloma.
T292	indication 29525 29541	Multiple Myeloma
T293	tradename 29547 29552	DOXIL
T294	co-administereddrug 29573 29583	Bortezomib
T295	tradename 29602 29607	DOXIL
T296	co-administereddrug 29610 29631	bortezomib Bortezomib
T297	adversereaction 29723 29734	Neutropenia
T298	adversereaction 29747 29763	Thrombocytopenia
T299	adversereaction 29776 29782	Anemia
T300	adversereaction 29846 29853	Fatigue
T301	adversereaction 29864 29871	Pyrexia
T302	adversereaction 29882 29890	Asthenia
T303	adversereaction 29928 29934	Nausea
T304	adversereaction 29945 29953	Diarrhea
T305	adversereaction 29964 29972	Vomiting
T306	adversereaction 29983 29995	Constipation
T307	adversereaction 30006 30026	Mucositis/Stomatitis
T308	adversereaction 30040 30054	Abdominal pain
T309	adversereaction 30092 30105	Herpes zoster
T310	adversereaction 30115 30129	Herpes simplex
T311	adversereaction 30154 30170	Weight decreased
T312	adversereaction 30217 30225	Anorexia
T313	adversereaction 30265 30287	Peripheral Neuropathy1
T314	adversereaction 30299 30308	Neuralgia
T315	adversereaction 30319 30342	Paresthesia/dysesthesia
T316	adversereaction 30405 30410	Cough
T317	adversereaction 30460 30465	Rash2
T318	adversereaction 30476 30494	Hand-foot syndrome
T319	adversereaction 30574 30673	peripheral sensory neuropathy, neuropathy peripheral, polyneuropathy, peripheral motor neuropathy,
T320	adversereaction 30678 30688	neuropathy
T321	adversereaction 30743 30836	rash, rash erythematous, rash macular, rash maculo-papular, rash pruritic, exfoliative rash,
T322	adversereaction 30841 30858	rash generalized.
T323	tradename 30981 30987	DOXIL.
T324	adversereaction 31240 31253	muscle spasms
T325	adversereaction 31441 31459	pulmonary embolism
T326	adversereaction 31506 31542	Secondary acute myelogenous leukemia
T327	adversereaction 31584 31684	erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis Secondary oral neoplasms:
T328	tradename 31804 31810	DOXIL.
T329	tradename 31900 31905	DOXIL
T330	tradename 31998 32003	DOXIL
T331	routeofadministration 32067 32078	intravenous
T332	tradename 32596 32601	DOXIL
T333	dose 32630 32637	1 mg/kg
T334	frequency 32637 32641	/day
T335	dose 32691 32701	0.5 mg/kg/
T336	frequency 32701 32704	day
T337	dose 32773 32781	50 mg/m2
T338	tradename 32961 32966	DOXIL
T339	tradename 33149 33155	DOXIL,
T340	tradename 33204 33210	DOXIL.
T341	tradename 33419 33424	DOXIL
T342	tradename 33642 33648	DOXIL.
T343	tradename 33656 33661	DOXIL
T344	tradename 33899 33904	DOXIL
T345	tradename 34002 34007	DOXIL
T346	activeingredient 34091 34107	doxorubicin HCl.
T347	tradename 34180 34185	DOXIL
T348	tradename 34474 34479	DOXIL
T349	tradename 34568 34573	DOXIL
T350	indication 34619 34633	ovarian cancer
T351	indication 34652 34681	AIDS-related Kaposi's sarcoma
T352	tradename 34867 34872	DOXIL
T353	tradename 35349 35354	DOXIL
T354	tradename 35487 35492	DOXIL
T355	activeingredient 35574 35589	doxorubicin HCl
T356	adversereaction 35615 35644	severe mucositis, leukopenia,
T357	adversereaction 35649 35666	thrombocytopenia.
T358	tradename 35683 35688	DOXIL
T359	activeingredient 35690 35705	doxorubicin HCl
T360	nanoparticle 35706 35714	liposome
T361	activeingredient 35729 35754	doxorubicin hydrochloride
T362	chemoclass 35765 35806	anthracycline topoisomerase II inhibitor,
T363	nanoparticle 35831 35848	STEALTH liposomes
T364	routeofadministration 35853 35864	intravenous
T365	activeingredient 35892 35907	doxorubicin HCl
T366	molecularweight 36144 36151	579.99.
T367	tradename 36182 36187	DOXIL
T368	nanoparticle 36219 36228	liposomal
T369	activeingredient 36317 36332	doxorubicin HCl
T370	nanoparticle 36384 36400	STEALTH liposome
T371	corecomposition 36426 36438	cholesterol,
T372	corecomposition 36457 36501	hydrogenated soy phosphatidylcholine (HSPC),
T373	surfacecoating 36518 36634	N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero3-phosphoethanolamine sodium salt (MPEG-DSPE),
T374	inactiveingredient 36669 36686	ammonium sulfate,
T375	inactiveingredient 36707 36716	histidine
T376	inactiveingredient 36730 36747	hydrochloric acid
T377	inactiveingredient 37096 37112	sodium hydroxide
T378	inactiveingredient 37133 37140	sucrose
T379	nanoparticle 37218 37236	STEALTH liposomes.
T380	surfacecoating 37238 37247	MPEG-DSPE
T381	nanoparticle 37307 37324	STEALTH liposome:
T382	tradename 37403 37408	DOXIL
T383	activeingredient 37412 37428	doxorubicin HCl.
T384	activeingredient 37456 37471	doxorubicin HCl
T385	activeingredient 38013 38024	doxorubicin
T386	tradename 38052 38057	DOXIL
T387	activeingredient 38155 38166	Doxorubicin
T388	tradename 38172 38177	DOXIL
T389	indication 38195 38224	AIDS-Related Kaposi's Sarcoma
T390	dose 38250 38268	10 mg/m2 20 mg/m2
T391	cmax 38330 38341	4.12  0.215
T392	clearance 38342 38353	0.056  0.01
T393	cmax 38355 38365	8.34  0.49
T394	clearance 38366 38378	0.041  0.004
T395	volumeofdistribution 38416 38446	(L/m2) 2.83  0.145 2.72  0.120
T396	auc 38451 38486	(g/mL&#x2022;h) 277  32.9 590  58.7
T397	plasmahalflife 38513 38534	(h) 4.7  1.1 5.2  1.4
T398	plasmahalflife 38562 38585	(h) 52.3  5.6 55.0  4.8
T399	tradename 38613 38618	DOXIL
T400	dose 38671 38686	10 to 20 mg/m2.
T401	tradename 38699 38704	DOXIL
T402	dose 38723 38732	20 mg/m2,
T403	activeingredient 38763 38774	doxorubicin
T404	dose 38787 38795	50 mg/m2
T405	tradename 38796 38801	DOXIL
T406	tradename 38865 38870	DOXIL
T407	dose 38919 38927	20 mg/m2
T408	nanoparticle 38971 38980	liposomal
T409	activeingredient 38981 38992	doxorubicin
T410	activeingredient 39082 39094	doxorubicin)
T411	nanoparticle 39103 39124	liposome-encapsulated
T412	activeingredient 39161 39173	doxorubicin,
T413	volumeofdistribution 39227 39244	700 to 1100 L/m2)
T414	nanoparticle 39295 39304	liposomal
T415	activeingredient 39305 39316	doxorubicin
T416	tradename 39331 39336	DOXIL
T417	activeingredient 39376 39387	Doxorubicin
T418	nanoparticle 39416 39425	liposomes
T419	tradename 39470 39475	DOXIL
T420	activeingredient 39531 39542	doxorubicin
T421	activeingredient 39617 39629	doxorubicin,
T422	dose 39721 39735	10 or 20 mg/m2
T423	tradename 39736 39742	DOXIL.
T424	activeingredient 39956 39967	doxorubicin
T425	tradename 39973 39978	DOXIL
T426	clearance 39983 39995	0.041 L/h/m2
T427	dose 40009 40017	20 mg/m2
T428	activeingredient 40048 40064	doxorubicin HCl,
T429	activeingredient 40089 40100	doxorubicin
T430	clearance 40104 40119	24 to 35 L/h/m2
T431	tradename 40282 40288	DOXIL,
T432	activeingredient 40297 40308	doxorubicin
T433	tradename 40602 40607	DOXIL
T434	dose 40717 40725	36 mg/kg
T435	dose 40745 40753	50 mg/m2
T436	dose 40879 40889	0.25 mg/kg
T437	frequency 40889 40893	/day
T438	dose 40916 40924	50 mg/m2
T439	dose 41093 41100	1 mg/kg
T440	frequency 41100 41104	/day
T441	dose 41126 41134	50 mg/m2
T442	indication 41191 41205	Ovarian Cancer
T443	tradename 41207 41212	DOXIL
T444	indication 41296 41321	metastatic ovarian cancer
T445	tradename 41583 41588	DOXIL
T446	dose 41592 41600	50 mg/m2
T447	frequency 41601 41619	every 3 or 4 weeks
T448	duration 41624 41635	3-6+ cycles
T449	indication 42618 42632	Ovarian Cancer
T450	indication 42649 42663	Ovarian Cancer
T451	indication 43205 43219	ovarian cancer
T452	tradename 43298 43303	DOXIL
T453	dose 43304 43312	50 mg/m2
T454	frequency 43313 43326	every 4 weeks
T455	dose 43348 43357	1.5 mg/m2
T456	frequency 43358 43363	daily
T457	frequency 43387 43400	every 3 weeks
T458	tradename 44345 44350	DOXIL
T459	tradename 45151 45157	DOXIL.
T460	indication 45214 45243	AIDS-Related Kaposi's Sarcoma
T461	tradename 45244 45249	DOXIL
T462	dose 45323 45331	20 mg/m2
T463	frequency 45333 45347	every 3 weeks,
T464	activeingredient 45786 45802	doxorubicin HCl.
T465	duration 45833 45843	5.1 months
T466	duration 45851 45870	1 day to 15 months)
T467	tradename 45902 45907	DOXIL
T468	dose 45912 45921	154 mg/m2
T469	dose 45929 45945	20 to 620 mg/m2)
T470	indication 47568 47597	AIDS-Related Kaposi's Sarcoma
T471	tradename 48604 48609	DOXIL
T472	indication 48976 48992	Multiple Myeloma
T473	tradename 49009 49014	DOXIL
T474	co-administereddrug 49035 49045	bortezomib
T475	co-administereddrug 49179 49189	bortezomib
T476	tradename 49312 49317	DOXIL
T477	dose 49319 49328	30 mg/m2)
T478	routeofadministration 49342 49344	IV
T479	co-administereddrug 49364 49374	bortezomib
T480	dose 49376 49385	1.3 mg/m2
T481	routeofadministration 49386 49388	IV
T482	frequency 49434 49447	every 3 weeks
T483	duration 49452 49466	up to 8 cycles
T484	indication 49747 49763	multiple myeloma
T485	tradename 50047 50052	DOXIL
T486	co-administereddrug 50055 50065	bortezomib
T487	indication 50683 50699	Multiple Myeloma
T488	tradename 51258 51263	DOXIL
T489	co-administereddrug 51266 51276	bortezomib
T490	tradename 51631 51636	DOXIL
T491	co-administereddrug 51657 51667	Bortezomib
T492	indication 51702 51718	Multiple Myeloma
T493	tradename 51729 51734	DOXIL
T494	co-administereddrug 51737 51747	bortezomib
T495	tradename 52333 52339	DOXIL+
T496	co-administereddrug 52339 52350	bortezomib.
T497	tradename 52746 52751	DOXIL
T498	nanoparticle 52783 52792	liposomal
T499	activeingredient 52881 52896	doxorubicin HCl
T500	activeingredient 52961 52976	doxorubicin HCl
T501	tradename 53352 53357	DOXIL
T502	tradename 53416 53421	DOXIL
T503	adversereaction 53540 53554	Cardiomyopathy
T504	adversereaction 53636 53649	heart failure
T505	adversereaction 53689 53715	Infusion-Related Reactions
T506	adversereaction 53754 53780	infusion related reactions
T507	adversereaction 53898 53914	Myelosuppression
T508	adversereaction 53984 53989	fever
T509	adversereaction 54005 54035	infection. Hand-Foot Syndrome
T510	adversereaction 54107 54115	tingling
T511	adversereaction 54119 54182	burning, redness, flaking, bothersome swelling, small blisters,
T512	adversereaction 54186 54248	small sores on the palms of their hands or soles of their feet
T513	adversereaction 54262 54281	Hand-Foot Syndrome)
T514	adversereaction 54321 54331	Stomatitis
T515	adversereaction 54408 54426	redness, swelling,
T516	adversereaction 54430 54448	sores in the mouth
T517	adversereaction 54462 54473	stomatitis)
T518	adversereaction 54476 54496	Embryofetal Toxicity
T519	tradename 54854 54859	DOXIL
T520	tradename 54967 54972	DOXIL
T521	adversereaction 55106 55117	Infertility
T522	tradename 55174 55179	DOXIL
T523	adversereaction 55213 55224	infertility
T524	adversereaction 55267 55305	Discoloration of Urine and Body Fluids
T525	tradename 55337 55342	DOXIL
T526	company 55570 55586	ALZA Corporation
T527	company 55610 55630	TTY Biopharm Company
T528	company 55723 55743	Janssen Products, LP
T529	company 55763 55783	Janssen Products, LP
T530	tradename 55840 55845	DOXIL
T531	company 55875 55892	ALZA Corporation.
